Similarly, the loss of B cell-specific IL-35 expression or antibody-based IL-35 blockade synergized with anti-PD1 treatment in a CD8+ T cell-dependent manner to inhibit pancreatic cancer growth in preclinical models [169]. This evidence concerns the gene CD8A and pancreatic neoplasm.